Vir Biotechnology (VIR) Competitors

Vir Biotechnology (NASDAQ:VIR) and Relay Therapeutics (NASDAQ:RLAY) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, community ranking, earnings, valuation, institutional ownership and media sentiment.

Which has more risk & volatility, VIR or RLAY?

Vir Biotechnology has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500.

Does the media refer more to VIR or RLAY?

In the previous week, Vir Biotechnology had 3 more articles in the media than Relay Therapeutics. MarketBeat recorded 8 mentions for Vir Biotechnology and 5 mentions for Relay Therapeutics. Vir Biotechnology's average media sentiment score of 0.83 beat Relay Therapeutics' score of 0.71 indicating that Vir Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relay Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend VIR or RLAY?

Vir Biotechnology currently has a consensus price target of $36.40, suggesting a potential upside of 417.78%. Relay Therapeutics has a consensus price target of $21.22, suggesting a potential upside of 333.99%. Given Vir Biotechnology's higher possible upside, research analysts plainly believe Vir Biotechnology is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60
Relay Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

Does the MarketBeat Community favor VIR or RLAY?

Relay Therapeutics received 8 more outperform votes than Vir Biotechnology when rated by MarketBeat users. Likewise, 67.90% of users gave Relay Therapeutics an outperform vote while only 52.22% of users gave Vir Biotechnology an outperform vote.

Company	Underperform	Outperform
Vir Biotechnology	Outperform Votes 47 52.22%	Underperform Votes 43 47.78%
Relay Therapeutics	Outperform Votes 55 67.90%	Underperform Votes 26 32.10%

Is VIR or RLAY more profitable?

Relay Therapeutics has a net margin of 0.00% compared to Vir Biotechnology's net margin of -678.40%. Vir Biotechnology's return on equity of -36.71% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	-678.40%	-36.71%	-31.00%
Relay Therapeutics	N/A	-45.75%	-40.75%

Which has stronger earnings & valuation, VIR or RLAY?

Relay Therapeutics has lower revenue, but higher earnings than Vir Biotechnology. Relay Therapeutics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$86.18M	11.23	-$615.06M	-$3.92	-1.79
Relay Therapeutics	$10.01M	81.80	-$341.97M	-$2.61	-1.87

Do insiders and institutionals hold more shares of VIR or RLAY?

65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 15.6% of Vir Biotechnology shares are held by insiders. Comparatively, 4.3% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Relay Therapeutics beats Vir Biotechnology on 10 of the 18 factors compared between the two stocks.